News

Health Canada Allows ELEGANSE Trial for the Treatment of Lennox-Gastaut Syndrome

February 22, 2022
Epygenix Therapeutics, a clinical-stage biopharmaceutical company founded on UCSF researcher Scott Baraban's work and focused on rare and intractable genetic epilepsy, announced today that Health Canada issued a "No Objection Letter" (NOL) to proceed with the ELEGANSE trial for the treatment of...

UCSF Gets New Money to Study the 'Galaxies' Within You (Your Microbes)

February 15, 2022
This month the University of California at San Francisco for research about the human microbiome received $25 million to study them. Susan Lynch will direct the Benioff Center for Microbiome Medicine at UCSF.

Siolta Therapeutics Awarded NIH Grant

February 11, 2022
Siolta Therapeutics, a clinical-stage biopharmaceutical company developing novel microbiome-based targeted therapeutics developed by UCSF researcher Dr. Susan Lynch, today announced that it was awarded an Advanced Technology Small Business Innovation Research (SBIR) grant by the National Institute...

New CRISPR tool maps out routes to better immune cell therapies for cancer, autoimmune diseases

February 08, 2022
The CRISPR gene-editing system has offered scientists a powerful tool for studying the effects of altering specific genes. Now, researchers at the Gladstone-UCSF Institute of Genomic Immunology have devised a CRISPR platform that allowed them to discover new roles of genes in human T cells, which...

Diagnosis of Pain Causing Spinal Discs With MRS And SaaS

February 04, 2022
Aclarion, Inc. is a commercial-stage healthcare technology company that has developed a proprietary signal processing software to transform magnetic resonance spectroscopy ('MRS') data into clear biomarkers that can assist surgeons in optimizing clinical treatments. At the core of the technology is...

Mission Bio Transfers First Tapestri GMP-Ready CGT Assay to Avance Biosciences

February 04, 2022
 Mission Bio Inc., the pioneer in high-throughput single-cell DNA and multi-omics analysis developed by UCSF researcher Adam Abate, announced today the first tech transfer of a clinical trial-ready cell and gene therapy (CGT) assay from its Tapestri Platform to Avance Biosciences, Inc., a leading-...

UCSF cancer biologist Hani Goodarzi receives Vilcek Prize for Creative Promise

February 04, 2022
The Vilcek Foundation recognizes and celebrates the research contributions of computational biologist and cancer researcher Hani Goodarzi in a new article and video published on the foundation's website, Hani Goodarzi: A multidisciplinary approach to cancer biology. MORE

3 Researchers Named 2021 Fellows of American Association for the Advancement of Science

By Nina Bai on January 27, 2022
Three UC San Francisco researchers have been selected as 2021 fellows of the American Association for the Advancement of Science (AAAS), the world largest multidisciplinary scientific society and a leading publisher of cutting-edge research through its Science family of journals.  MORE

Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded

January 26, 2022
Akili Interactive, a leading digital medicine company developing cognitive treatments through game-changing technologies based on Adam Gazzaley's University of California, San Francisco research, has entered into a definitive agreement to become publicly traded via a merger with Social Capital...

ArsenalBio Announces Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors

January 11, 2022
Bristol Myers Squibb exercises option to initiate new program under the December 2020 agreement. Strategic collaboration combines ArsenalBio’s programmable cell therapy approach with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development.  

Pages